businetvs - 28/05/2009 - bertrand ducrey, debio recherche pharmaceutique
DESCRIPTION
COMMENT RESTER PERFORMANT EN INNOVANT ?TRANSCRIPT
2 © Debiopharm Group 200928.05.2009
. LausanneMartigny
Paris..Montreal
Debiopharm Group
Founded in 1979, privately owned, financially independant 300 Employees worldwide with headquarters in Lausanne,
Switzerland 42 % scientists (MDs, PhDs, pharmacists)
> 400 international network of experts ‘on call’ Key expertise : Drug Development
3 © Debiopharm Group 200928.05.2009
Business Model: Bridging Discovery to Market
Fully funded drug development
& innovation
Discovery
Pharmasanofi-aventis, Ipsen, Watson, Pfizer and others
DEBIOPHARM GROUP
from molecule to drug approval
Market
Academic institutionsBiotechStart upPharmaKirin, EPFL, Tulane University, Shanghai Institute (SIMM),Nanocarrier and others
Added Value
4 © Debiopharm Group 200928.05.2009
.
Eloxatin ® awarded 2004 Prix Galien
- Indications: 1st line, 2nd line, adjuvant, neoadjuvant metastatic colorectal cancer
- sanofi-aventis’ # 6 product- Current licensee sales : 2.3 billion USD
Decapeptyl ® and Trelstar ® (USA)Indications: advanced prostate cancer,
endometriosis, precocious puberty, uterine fibroids, Paraphilia
- Ipsen’s # 1 product- Current licensee sales: 400 million USD
Our products
5 © Debiopharm Group 200928.05.2009
Poly-Lactide-Glycolide : PLG
HydrolysisLactic acid + Glycolic acid
Degradation time (1 week to 6 months) function of :
• Ratio L:G
• Mw (Inherant viscosity, i.v.)
• Terminal end groups (laurylester, PEG, -COOH)
6 © Debiopharm Group 200928.05.2009
Pt loaded Polymeric Nano-Micelles
MeO (CH2CH2O)n NH CO
CHHN
CH2
CH2
CO ONa
H
m
CH2CH2CH2
H2N
PtOOCN
H2
OOC COOPt
NH2H2N
OOC
+
H2N
NH2
Pt
ONO2
ONO2
Mean diameter
30 nm
7 © Debiopharm Group 200928.05.2009
Pt loaded Polymeric Nano-Micelles
Total Platinum in plasma in C38 mouse model after IV injection of ND formulations or L-OHP
10
100
1000
10000
100000
0 24 48 72 96
hours
ng
Pt/
ml
L-OHP (060016)
L-OHP (060048)
ND-01-01 (060048)
ND-01-02 (060016)
ND-01-03 (060016)
AUC 0-96h total platinum in tumor
020000400006000080000
100000120000140000160000180000200000
l-OHP ND-01-01
ng P
t/g.h
8 © Debiopharm Group 200928.05.2009
In vivo bioluminescent imaging (IVIS Imaging System, Xenogen) HeLa-Luc i.p metastases at day 15 (D-luciferin injected at 150 mg/kg 10 minutes before)
B. Saline; C. oxaliplatin 6 mg/kg; D. DACHPt micelles 6 mg/kg.
Antitumor Activity assay
9 © Debiopharm Group 200928.05.2009
O
Re-design of Drugs
EXAMPLE: synthesis of Debio-025 (Anti-HcV)
Immunosuppressive Antiviral
10 © Debiopharm Group 200928.05.2009
Conclusion: Origine de l’innovation
Bottom up (production) Curiosité, analyse (comprendre pour innover, améliorer)
Top down (R&D) Association d’idées différentes Expression du besoin Idées de ruptures/passer les barrières Confronter des visions différentes